SMAD3 and cancer: We demonstrated that pharmaceutical inhibition of Smad3 with the specific inhibitor SIS3 effectively blocked MNT as well as the associated tumor innervation (Tubb3+ and NeuN+ cells) and cancer-associated spontaneous nocifensive behaviors of the LLC-bearing mice (Fig. 6, H and I).